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Abstract
Background: In Italy, a large cohort study (VEdeTTE1) was conducted between 1998–2001 to evaluate the
effectiveness of treatments in reducing mortality and increasing treatment retention among heroin addicts. The
follow-up of this cohort (VEdeTTE2) was designed to evaluate the effectiveness of treatments on long-term
outcomes, such as rehabilitation and social re-integration. The purpose of this paper is to describe the protocol
of the VEdeTTE2 study, and to present the results of the pilot study carried out to assess the feasibility of the
study and to improve study procedures.
Methods: The source population for the VEdeTTE2 study was the VEdeTTE1 cohort, from which a sample of
2,200 patients, traced two or more years after enrolment in the cohort, were asked to participate. An interview
investigates drug use; overdose; family and social re-integration. Illegal activity are investigated separately in a
questionnaire completed by the patient. Patients are also asked to provide a hair sample to test for heroin and
cocaine use. Information on treatments and HIV, HBV and HCV morbidity are obtained from clinical records. A
pilot phase was planned and carried out on 60 patients.
Results: The results of the pilot phase pointed out the validity of the procedures designed to limit attrition: the
number of traced subjects was satisfactory (88%). Moreover, the pilot phase was very useful in identifying possible
causes of delays and attrition, and flaws in the instruments. Improvements to the procedures and the instruments
were subsequently implemented. Sensitivity of the biological test was quite good for heroin (78%) but lower for
cocaine (42.3%), highlighting the need to obtain a hair sample from all patients.
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Conclusion: In drug addiction research, studies investigating health status and social re-integration of subjects
at long-term follow-up are lacking. The VEdeTTE2 study aims to investigate these outcomes at long-term follow-
up. Results of the pilot phase underline the importance of the pilot phase when planning a follow-up study.
1 Background
Apart from excess mortality [1-5], the health effects of her-
oin use are related to: the direct effects of drug use (e.g.
overdose); concurrent psychiatric pathologies (e.g. sui-
cide); injections (e.g. HIV, hepatitis, site infections); and
the social effects (e.g. unemployment, criminal activity,
prostitution, deterioration of family and social relations)
[6].
In the short-term, drug abuse treatment aims to protect
subjects from overdose and infections, and lower the risk
of death. In the mid- to long-term, treatment is aimed at
social re-integration and, therefore, rehabilitation. Cohort
studies investigating the effects of treatment for heroin
addiction (DARP, TOPS, NTORS, DATOS, Amsterdam
Cohort Study) have been conducted in various countries.
Data on heroin and cocaine use, overdose, mortality,
crime and illegal activity have been evaluated in short-
term follow-up studies [7-18]. Mortality data and sub-
stance use have been evaluated also in long-term follow-
up [1,2,10,15,17,19-22]. However, few studies have
assessed social rehabilitation and re-integration in mid- to
long-term follow-up [15,19,23-25], and very few have
evaluated the relationship between outcomes and drug
abuse treatment [15,19].
In Italy, the first phase of a large multicentre cohort study
on heroin addicts, known as VEdeTTE (Italian acronym
for "Evaluation of Effectiveness of Treatments for Heroin
Dependence") [26], was conducted between 1998 and
2001. The main aim of the study was to evaluate the effec-
tiveness of treatments in reducing mortality and increas-
ing retention in treatment. The first phase, referred to as
VEdeTTE1, involved 115 drug abuse treatment centres of
the National Health Service (NHS). The enrolled popula-
tion consisted in 11,903 Italian heroin addicts, aged 18
years or older, who received treatment at the participating
centres during the study period [26].
The follow-up of a sample of the VEdeTTE1 cohort was
organized to evaluate the effectiveness of treatments with
regard to long-term legal and illegal drugs use; overdose;
family and social re-integration; and HIV, HBV and HCV
morbidity. Forty-two NHS drug abuse treatment centres
participated in this second phase, referred to as VEdeTTE2,
which came to an end in December 2006. The assessment
of long-term outcomes other than mortality involves trac-
ing patients and obtaining their consent again, which
requires good study design and well-organized field work.
Moreover, in conducting a follow-up study several critical
methodological issues must be considered, such as attri-
tion and the accuracy of self-reported drug use.
To evaluate the feasibility of the VEdeTTE2 study and to
ensure the quality of follow-up procedures, a pilot study
was conducted in 2001. The purpose of this paper is to
describe the VEdeTTE2 study design and protocol, and to
present the results of the pilot study and the improve-
ments to the protocol implemented in consequence of the
pilot study.
2 VEdeTTE2 study protocol
2.1 Study population
The study population of the VEdeTTE2 study consist of a
sample of patients enrolled in the VEdeTTE1 cohort
between September 1998 and March 2001: all new
patients and a random sample of re-entry and prevalent
patients. The follow-up period is a minimum of two years
between the first interview in VEdeTTE1 and the
VEdeTTE2 follow-up interview. A sample size of 824 is
required to find a statistically significant Relative Risk of
1.5, with an alpha error of 0.05, a beta error of 10% and
an estimated prevalence of heroin users of 20%. However,
based on available funds, it was decided to follow-up
2,200 patients.
2.2 Consent form and confidentiality of data
All procedures and instruments were approved by the Eth-
ical Committee. A telephone number to contact the Ethi-
cal Committee is specified on the written consent form, a
copy of which is given to the patient at the time of enrol-
ment. Precautions are taken to guarantee data confidenti-
ality. Data are identified using the same anonymous code
assigned to the patient upon enrolment in VEdeTTE1. The
possibility of matching the anonymous code with patient
identity is restricted to the NHS treatment centres and the
Regional Coordinating Centres. Moreover, patients are
assigned to interviewers whom they have never met
before, and they have the choice of being interviewed out-
side the NHS treatment centre. Finally, only aggregate
results will be communicated to NHS treatment centres.
2.3 Tracing procedures
To minimize attrition and achieve a good contact rate,
detailed procedures were devised. First of all, a reward is
given to participating patients, as suggested in the interna-
tional literature [27,28]. Patients are given 15 euro for the
interview and 37 euro for the biological sample. Secondly,Substance Abuse Treatment, Prevention, and Policy 2007, 2:9 http://www.substanceabusepolicy.com/content/2/1/9
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the interviewers are either external interviewers or NHS
treatment centre personnel; they are trained in a one-day
training session, and paid 129 euro for each interview and
15 euro for each refusal or drop-out. Thirdly, accurate trac-
ing procedures were implemented. For patients still
attending NHS treatment centres, the interviewer is intro-
duced to the patient by a clinician at the treatment centre.
For patients no longer attending the drug treatment cen-
tre, the interviewer contacts the patient with the help of
treatment centre personnel. In the case of failure, life sta-
tus and home address are obtained at the General Registry
Office and, whenever possible, a phone number from the
patient's acquaintances. Finally, a maximum of three
attempts are made to contact the patient by letter sent to
the last known address.
2.4 Interview and questionnaire
Participants are required to complete a questionnaire
administered by an interviewer. The questionnaire con-
sists of eleven sections: 1) civil status, educational level,
accommodation, job (to be completed for refusals and
drop-outs only); 2) HIV, HBV and HCV test results, other
pathologies recorded in the case history; 3) changes in
civil status, educational level and life events since the
VEdeTTE1 interview (e.g. marriage, divorce, births); 4)
self-reported pathologies; 5) illegal activity; 6) drug use
since the VEdeTTE1 interview (frequency, dose, route of
administration); 7) overdose; 8) use of legal drugs with-
out a medical prescription; 9) drug use in the last 30 days
(frequency, dose, route of administration); 10) risky
behaviours; 11) educational level, accommodation, job,
friendships, financial help, hobbies. The first section for
refusals and drop-outs is completed from information in
the clinical records. Most of the above items were investi-
gated in the interview upon enrolment in the VEdeTTE1
cohort, thereby allowing a comparison to be made
between the social and health status of the patients in the
two time periods.
Information on treatment is collected from clinical
records and recorded on a specific Registration Form
beginning with the first treatment received during the
VEdeTTE1 study period until the end of the VEdeTTE2
study. Details are collected on each treatment: type, dose,
start and end dates. All types of treatment used in the NHS
treatment centres are recorded: pharmacological treat-
ments (methadone and buprenorphine maintenance or
detoxification, psychotropic drugs, naltrexone, detoxifica-
tion with non-opiate drugs), psychosocial treatments
(counselling, social advice, psychotherapy, job guidance),
in-patient detoxification, semi-residential treatment and
residential therapeutic community.
2.5 Biological sample
Participating patients are also required to provide a sam-
ple of nape, axillary or pubic hair. Hair analysis is per-
formed to ascertain the reliability of self-reported drug use
[29-34]. In order to have information on drug use in the
last 30 days, and as hair grows between 0.8 and 1.4 cm per
month, interviewers collect hair from the nape if at least
one cm long, otherwise from the pubic (preferably) or
axillary areas. Morphine and 6-monoacetylmorphine are
examined as markers of heroin use; cocaine and its metab-
olite benzoylecgonine are the markers of cocaine use
[35,36]. The test results are qualitative (positive/negative),
with a quantitative measure (ng/mg of hair) for specimens
that screened positive or uncertain. To give a reliable esti-
mate of the last 30 days use, both the length of the sample
and the site of the body from which hair is collected will
be taken into account at the statistical analysis stage.
3 Pilot study
A pilot study was carried out to verify the feasibility of the
follow-up procedures. The specific objectives of the pilot
study were:
- to assess the feasibility of the VEdeTTE2 study with
regard to the effectiveness of contact procedures and
patients' acceptance rate;
- to compare the contact rate of external interviewers and
NHS drug abuse treatment centre personnel;
- to test the acceptability of study instruments (question-
naire, biological sample, monitoring form), for both
patients and interviewers;
- to evaluate the reliability of self-reported drug use, by
comparison with hair test results.
The pilot study was carried out in the Piedmont region
between April and June 2001, involving 10 NHS drug
abuse treatment centres. Piedmont was chosen based on
the availability of a regional ad hoc fund; moreover, 26%
of the participants in the VEdeTTE1 study were in Pied-
mont, and this subgroup was representative of the entire
cohort. From these 1,062 patients, 60 were selected for the
pilot study: all new patients and a random sample of re-
entry and prevalent patients. To assess the difference in
contact rate, patients were randomly assigned to three
external interviewers (29 patients) and three NHS treat-
ment centre personnel (31 patients).
3.1 Results
At the beginning of the pilot phase, an average of 28
months after enrolment in VEdeTTE1, 51 (85%) patients
were still attending NHS treatment centres, of whom 40
(78.4%) were interviewed, eight (15.7%) refused andSubstance Abuse Treatment, Prevention, and Policy 2007, 2:9 http://www.substanceabusepolicy.com/content/2/1/9
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three (5.9%) were not traced. Of the nine patients no
longer attending treatment centres, only one (11.1%) was
interviewed, two (22.2%) refused, one (11.1%) was dead,
one (11.1%) was living abroad and four (44.4%) were not
traced. The proportion not traced among patients no
longer attending NHS treatment centres (44.4%) was sig-
nificantly higher than among those still in attendance
(5.9%) (Fisher's exact test p = 0.007).
Five of the six patients living in a therapeutic community
were interviewed. The only patient in prison was declared
a drop-out, as it was impossible to contact the patient,
although many attempts had been made. The two patients
who had migrated to another Italian region were searched
for by telephone and through their acquaintances; one of
them was contacted but not interviewed, because of
administrative problems.
By the end of the pilot study, 53 patients (88.3%) had
been traced; 41 (68.3%) had been interviewed, 10
(16.6%) had refused, one (1.7%) was dead, one was liv-
ing abroad (1.7%), and seven (11.7%) were untraceable
(Table 1). A description of the 41 patients who were inter-
viewed for the pilot study is given in table 2. The median
follow-up period at the time of the interview was 29
months.
The difference in contact rate between external interview-
ers (100%, 29/29) and NHS treatment centre personnel
(71%, 22/31) was statistically significant (Fisher's exact
test p = 0.002), even after excluding the two untraceable
patients (one dead and one living abroad) who had been
both assigned to NHS treatment centre personnel. There
was no difference, however, between the proportions of
patients interviewed among those that had been traced:
79% (23/29) and 82% (18/22) respectively.
All except one of the 41 patients interviewed provided a
biological sample (33 nape hair, 5 axillary hair, 2 pubic
hair). Two samples (5%, 1 nape and 1 axillary hair) were
not analysed because the quantity was inadequate; seven
samples (17.5%, 4 nape and 3 axillary hair) screened neg-
ative owing to an inadequate quantity or inhomogeneous
length. The axillary hair samples were not reliable: most of
them were inadequate in quantity or inhomogeneous in
length. Of the remaining 31 samples, 58.1% screened pos-
itive for heroin (18/31) and 67.7% for cocaine (21/31).
For heroin, sensitivity was 78% and specificity 85%; for
cocaine, sensitivity and specificity were 43% and 100%
respectively (Table 3).
3.2 Improvements to procedures in the VEdeTTE2 study
On the basis of the pilot phase, the VEdeTTE2 study was
judged feasible. Contact procedures succeeded in tracing
88% (53/60) of patients, consistent with other studies
[37], and the acceptance rate was good (77%, 41/53). For
the biological sample, the acceptance rate was unexpect-
edly high (97.6%, 40/41).
The interviewer incentive scheme was successful. How-
ever, to encourage interviewers to obtain the consent of as
many patients as possible and to avoid the temptation to
contact only those patients still attending the NHS treat-
ment centres, the interviewer reward was changed slightly
in the main study. Interviewers received 90 euros for every
completed interview, with an extra 100 euros for each
additional interview after 50% of their assigned patients
had been interviewed; and 5 euros for each refusal or
drop-out.
As treatment centre personnel had a lower contact rate
than external interviewers, it was decided that no more
than half of the interviewers would be NHS treatment cen-
tre personnel, and that they would be assigned fewer
patients compared to external interviewers. To overcome
the difficulties encountered in contacting the patient in
prison, a request for official authorization was sent to the
Ministry of Justice. The Ministry of Justice sent a statement
of collaboration to all the prisons involved to facilitate the
work of the interviewers.
Table 1: Pilot study tracing results, by sex and patient classification
Consent Refusal Dead Abroad Total traced Dropped-out Total
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Males 25 (67.6) 7 (18.9) 0 (0.0) 1 (2.7) 33 (89.2) 4 (10.8) 37 (100)
Females 16 (69.6) 3 (13.0) 1 (4.3) 0 (0.0) 20 (87.0) 3 (13.0) 23 (100)
New 16 (66.7) 3 (12.5) 0 (0.0) 1 (4.2) 20 (83.4) 4 (16.7) 24 (100)
Re-entry 2 (100) 0 (0.0) 0 (0.0) 0 (0.0) 2 (100) 0 (0.0) 2 (100)
Prevalent 23 (67.6) 7 (20.6) 1 (2.9) 0 (0.0) 31 (91.2) 3 (8.8) 34 (100)
Total 41 (68.3) 10 (16.6) 1 (1.7) 1 (1.7) 53 (88.3) 7 (11.7) 60 (100)Substance Abuse Treatment, Prevention, and Policy 2007, 2:9 http://www.substanceabusepolicy.com/content/2/1/9
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Other changes were introduced: the monitoring forms
were simplified accordingly to the comments provided by
the interviewers; the sections in the questionnaire were re-
ordered with questions about demographic characteristics
at the beginning, and the more intrusive ones (e.g. drug
use, overdose, health status) toward the end; instructions
for both the questionnaire and the collection of the bio-
logical sample were improved. Moreover, in order to
deepen the investigation into illegal activity, a twelfth sec-
tion was developed that included questions about crimi-
nal activity and prostitution. This section was on a
separate sheet, which was given to the patient to be com-
pleted and returned by regular mail. The hope was that
this procedure would encourage patients to answer hon-
estly, without fear of legal consequences.
Sensitivity of the biological test was quite good for heroin
(78%), but not for cocaine (42.3%). This may be owing to
the inconsistency between the length of the hair examined
(2–4 cm corresponding to 2–4 months) and the recall
period in the questionnaire (30 days). Patients who had
used drugs two or three months prior to the interview but
not within the last 30 days would have screened positive
and given a negative response on the questionnaire. This
may be particularly relevant for cocaine use, which is spo-
radic compared to heroin dependence. On the other
hand, the fact that two patients reported heroin use on the
questionnaire but screened negative may suggest that the
biological test lacks the power to detect sporadic drug use.
Moreover, even though all samples that screened positive
were confirmed by gas chromatography-mass spectrome-
try, certain laboratory errors, such as false positives caused
by contamination in the laboratory, could have been
more thoroughly addressed had there been more speci-
mens. This is unlikely to affect the final results in the
VEdeTTE2 main study, as there were a large number of
samples. In order to improve the results in the main study,
only the two centimetres of hair nearest the root was
tested and patients were asked about their drug use in the
last two months.
4 Discussion
In Italy, there have not been any large follow-up studies of
heroin addicts evaluating rehabilitation outcomes in the
long term. The scarcity of international data on long-term
rehabilitation outcomes and the availability of a large
sample such as the VEdeTTE1 cohort as a source of poten-
tial subjects were the reasons for undertaking the follow-
up study. Moreover, the VEdeTTE1 study, because of its
study design, could investigate the effect of different treat-
ments and combinations of treatments on retention and
mortality [38], but not on drug use. The VEdeTTE2 follow-
up study, which combines self-reported measures with the
results of a biological sample, will provide a more reliable
assessment of drug use and, therefore, is a good occasion
Table 2: Characteristics of the 41 patients interviewed for the 
Pilot Study
Characteristic N %*
Gender
Males 25 61.0
Females 16 39.0
Typology of patients
New 11 26.8
New for VEdeTTE1 study 5 12.2
Re-entry 2 4.9
Prevalent 23 56.1
Education
< 9 years of school 29 70.7
9 – 13 years of school 11 26.8
> 13 years of school 0 0.0
Missing 1 2.4
Employment
Steady job 24 58.5
Temporary job 3 7.3
Unemployed/non-working status 12 29.3
Missing 2 4.9
Self-reported use in the last 30 days**
Heroin 19 46.3
Cocaine 11 26.8
Ecstasy 1 2.4
Cannabis 8 19.5
Alcohol 10 24.4
Age Mean SD
Age at time of VEdeTTE2 interview 32.9 6.2
Age at first heroin use 19.3 4.7
Age at first NHS drug abuse treatment 24.6 5.8
* proportion out of the total number of interviewed patients (n = 41)
** multiple answersSubstance Abuse Treatment, Prevention, and Policy 2007, 2:9 http://www.substanceabusepolicy.com/content/2/1/9
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for a thorough investigation into the effects of treatments
on long-term drug use.
The aim of this paper is to describe the VEdeTTE2 study
design and protocol, and to present the results of the pilot
study underlining the changes to the instruments conse-
quently implemented.
The results of the pilot phase pointed out the validity of
the procedures designed to limit attrition: the number of
traced subjects was satisfactory (88%). Moreover, the pilot
phase was very useful in identifying possible causes of
delays and attrition. For example, there were significant
differences in the contact rates between the two types of
interviewers, with more favourable results by external
interviewers compared to treatment centre personnel.
This could be probably due to differences in the availabil-
ity of dedicated time between the two categories of inter-
viewers. In consequence of this result, the number of NHS
interviewers was limited to 50% of the total.
Study instruments contained some flaws, identified by the
interviewers, which were consequently modified.
The self-reported drug use is a crucial item of a study
aimed at measuring the use of substances. For this reason,
it is generally recommended to collect a biological sample
in order to have a reliable measure of drug use. In the pilot
phase, sensitivity of the biological test was quite good for
heroin (78%) but lower for cocaine (42.3%). This result
confirmed the need to obtain a hair sample from all
patients.
These results underline the importance of the pilot phase
when planning a follow-up study, especially when heroin
addicted are involved.
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